List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 10 studies with search of: WAGR
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Conditions: WAGR Syndrome;   Wilm's Tumor;   Aniridia;   Urogenital Abnormalities;   Mental Retardation
Intervention:
2 Recruiting Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Conditions: Leukemia, Acute Myelogenous (AML);   Leukemia, Acute Lymphocytic (ALL);   Leukemia, Chronic Myelogenous (CML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: WT1 Peptide-Pulsed Dendritic Cells;   Drug: Donor Lymphocytes;   Drug: IL-4;   Drug: KLH;   Drug: WT1 Peptides;   Drug: Endotoxin
3 Completed Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: WT1 and PR1 Peptide Vaccine
4 Completed WT1 for the Detection of Minimal Residual Disease
Conditions: Leukemia;   Cancer
Intervention: Procedure: WT 1 Testing
5 Recruiting Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
Conditions: Myelodysplastic Syndrome (MDS);   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML)
Interventions: Biological: WT1:126-134 Peptide;   Biological: PR1:169-177 Peptide;   Drug: GM-CSF (Sargramostim);   Drug: WT1 and PR1 Peptide Vaccines;   Biological: WT1 and PR1 Peptide Vaccines
6 Completed Vaccination for Patients With High Risk Cancers of the Blood
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML)
Intervention: Drug: WR 1 and PR 1 Peptide Vaccine
7 Terminated Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines
Condition: Leukemia
Intervention: Biological: Autologous Dendritic Cells
8 Recruiting A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
Condition: Acute Myeloid Leukemia
Interventions: Drug: conventional chemotherapy (AraC + Daunorubicin),;   Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
9 Active, not recruiting Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
Conditions: Acute Leukaemia;   Chronic Disease;   Leukemia;   Myelodysplasia;   Lymphoma
Interventions: Drug: Busulfan;   Drug: Anti-Thymocyte Globulin;   Drug: Fludarabine;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil
10 Recruiting Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Biological: GM-K562 cell vaccine;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis

Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services